PDS Biotechnology Corp financial data

Symbol
PDSB on Nasdaq
Location
303 A College Road East, Princeton, NJ
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 266 % -41.9%
Debt-to-equity 134 % +24.5%
Return On Equity -185 % -34.7%
Return On Assets -79 % -19.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 46.6M shares +26.7%
Common Stock, Shares, Outstanding 46.6M shares +26.8%
Entity Public Float 104M USD -30.1%
Common Stock, Value, Issued 15.4K USD +26.8%
Weighted Average Number of Shares Outstanding, Basic 45.9M shares +25.1%
Weighted Average Number of Shares Outstanding, Diluted 45.9M shares +25.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 21.4M USD -15%
General and Administrative Expense 12.9M USD -11.5%
Operating Income (Loss) -34.3M USD +13.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -37.8M USD -2.58%
Income Tax Expense (Benefit) -270K USD
Net Income (Loss) Attributable to Parent -36.6M USD +10%
Earnings Per Share, Basic 0 USD/shares +25.2%
Earnings Per Share, Diluted 0 USD/shares +25.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 31.9M USD -44.8%
Assets, Current 33.6M USD -44.1%
Property, Plant and Equipment, Net 131K USD -14.3%
Operating Lease, Right-of-Use Asset 0 USD -100%
Assets 40.5M USD -33.1%
Accounts Payable, Current 4.5M USD +38.3%
Accrued Liabilities, Current 1.48M USD -23.9%
Liabilities, Current 11.5M USD -26.4%
Operating Lease, Liability, Noncurrent 0 USD
Liabilities 24.5M USD -17.1%
Retained Earnings (Accumulated Deficit) -200M USD -22.4%
Stockholders' Equity Attributable to Parent 16M USD -48.4%
Liabilities and Equity 40.5M USD -33.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.03M USD +9.12%
Net Cash Provided by (Used in) Financing Activities 7.32M USD -63.4%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 46.6M shares +26.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 31.9M USD -44.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 694K USD -40.9%
Deferred Tax Assets, Valuation Allowance 64.7M USD +14.1%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 64.7M USD +14.1%
Operating Lease, Liability 59.7K USD -84.9%
Depreciation 5.46K USD +15.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -36.6M USD +10%
Lessee, Operating Lease, Liability, to be Paid 60.3K USD -85.6%
Property, Plant and Equipment, Gross 296K USD +10.9%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year One 0 USD -100%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 683 USD -97%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Current Income Tax Expense (Benefit) 0 USD
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 0 USD -100%
Additional Paid in Capital 216M USD +11.1%
Deferred Tax Assets, Net of Valuation Allowance 46.6K USD -17.9%
Share-based Payment Arrangement, Expense 448K USD -75.1%
Interest Expense 4.41M USD +93.3%